Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle

Eli Lilly, AbbVie, and AstraZeneca are racing to acquire in vivo CAR T platforms, which manufacture cancer-fighting cells inside the patient's body rather than in labs, potentially lowering costs and broadening access. Safety—maintaining precision and control once the genetic material is inside the patient—remains the critical regulatory and commercial hurdle that will determine winners in this emerging modality.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.